Exact Mass: 421.0724

Exact Mass Matches: 421.0724

Found 16 metabolites which its exact mass value is equals to given mass value 421.0724, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Neurokinin-1 Receptor Antagonist

N-(3-Chlorophenyl)-2-{[4-phenyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl]sulphanyl}ethanimidic acid

C21H16ClN5OS (421.0764)


   

Asn-Phe4Cl-OH

(S)-2-(3-(2-amino-2-oxoethoxy)-4-nitrobenzamido)-3-(4-chlorophenyl)propanoic acid

C18H16ClN3O7 (421.0677)


   

Phe4Cl-Asn-OH

(S)-5-amino-2-(3-((4-chlorobenzyl)oxy)-4-nitrobenzamido)-5-oxopentanoic acid

C18H16ClN3O7 (421.0677)


   

Neurokinin-1 Receptor Antagonist

Neurokinin-1 Receptor Antagonist

C21H16ClN5OS (421.0764)


   

Bis(myo-inositol) 1,3-phosphate

Bis(myo-inositol) 1,3-phosphate

C12H22O14P- (421.0747)


   

2-O-sulfo-alpha,alpha-trehalose

2-O-sulfo-alpha,alpha-trehalose

C12H21O14S- (421.0652)


   

alpha-L-galactopyranose-6-sulfate-(1,3)-beta-D-galactose

alpha-L-galactopyranose-6-sulfate-(1,3)-beta-D-galactose

C12H21O14S- (421.0652)


   

(2S)-2-[4-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]anilino]butanedioic acid

(2S)-2-[4-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]anilino]butanedioic acid

C15H20NO11P (421.0774)


   

[4-(Butan-2-ylamino)-6-chloro-1,3,5-triazin-2-yl]-[(1,1,3-trioxo-1,2-benzothiazol-2-yl)methyl]cyanamide

[4-(Butan-2-ylamino)-6-chloro-1,3,5-triazin-2-yl]-[(1,1,3-trioxo-1,2-benzothiazol-2-yl)methyl]cyanamide

C16H16ClN7O3S (421.0724)


   

2-[[[5-(3-chlorophenyl)-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]thio]methyl]-1H-benzimidazole

2-[[[5-(3-chlorophenyl)-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]thio]methyl]-1H-benzimidazole

C21H16ClN5OS (421.0764)


   

2-[[4-(2-Methoxyphenyl)sulfonyl-1-piperazinyl]sulfonyl]benzonitrile

2-[[4-(2-Methoxyphenyl)sulfonyl-1-piperazinyl]sulfonyl]benzonitrile

C18H19N3O5S2 (421.0766)


   

3-(Tert-butylsulfamoyl)-4-phenyl-5-(trifluoromethyl)-2-thiophenecarboxylic acid methyl ester

3-(Tert-butylsulfamoyl)-4-phenyl-5-(trifluoromethyl)-2-thiophenecarboxylic acid methyl ester

C17H18F3NO4S2 (421.0629)


   

2-[[5-(4-chlorophenyl)-1-(2-methoxyethyl)-2-imidazolyl]thio]-N-(thiophen-2-ylmethyl)acetamide

2-[[5-(4-chlorophenyl)-1-(2-methoxyethyl)-2-imidazolyl]thio]-N-(thiophen-2-ylmethyl)acetamide

C19H20ClN3O2S2 (421.0685)


   
   

[(2R,3S,4R,5R)-3,4-dihydroxy-5-[2-[(1-hydroxy-2-oxoethyl)amino]-6-oxo-1H-purin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate

[(2R,3S,4R,5R)-3,4-dihydroxy-5-[2-[(1-hydroxy-2-oxoethyl)amino]-6-oxo-1H-purin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate

C12H16N5O10P (421.0635)


   

UNC9995

UNC9995

C20H21Cl2N3OS (421.0782)


UNC9995 is a β-arrestin2-biased agonist of dopamine receptor Drd2. UNC9995 inhibits NLRP3 inflammasome activation by enhancing β-arrestin2-NLRP3 interaction, thus prevents neuronal degeneration. Futhermore, UNC9995 activates the Drd2/β-arrestin2 signaling to prevent inflammation-related genes transcription-induced by JAK/STAT3. UNC9995 improves depressive behavior in mouse model, and improves astrocytes dysfunctions[1].